Yüklüyor......
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogra...
Kaydedildi:
| Yayımlandı: | Int J Mol Sci |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4519957/ https://ncbi.nlm.nih.gov/pubmed/26204829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160716414 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|